Drug
Lnk01001
Lnk01001: highest development phase Phase 3, developed by Lynk Pharmaceuticals Co., Ltd. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Lynk Pharmaceuticals Co., Ltd
Trials
| Drug | Phase | Indication |
|---|---|---|
| LNK01001 NCT06276998 | Phase 3 | Rheumatoid Arthritis |
| LNK01001 NCT07237568 | Phase 3 | Ankylosing Spondylitis |
Latest
No recent events.
Follow Lnk01001 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.